- HMBD-501 is a HER3-targeting antibody-drug conjugate (ADC) developed by Hummingbird Bioscience, featuring a unique mechanism of action designed for superior safety and effectiveness.
SINGAPORE, Jan. 06, 2026 – Hummingbird Bioscience, a biotherapeutics firm focused on discovering and developing innovative treatments for conditions with substantial unmet medical needs, declared today that the initial patient has received a dose in a Phase I clinical trial of HMBD-501, intended for individuals suffering from advanced HER3-expressing solid cancers ().
HMBD-501 represents a cutting-edge HER3-targeted antibody-drug conjugate (ADC) utilizing an exatecan payload, meticulously optimized for both safety and effectiveness. Hummingbird Bioscience is conducting the Phase I clinical trial across several locations within the U.S.
“Administering the first dose to a patient in this trial marks a crucial achievement for the HMBD-501 initiative, stemming from years of dedicated HER3 research and development by the Hummingbird Bio team. We are now eager to produce robust clinical data that will inform the subsequent stages of development,” stated Jerome Boyd-Kirkup, PhD, Chief Scientific Officer at Hummingbird Bioscience.
“The dosing of the first patient signifies a substantial advancement as we commence evaluating our experimental therapy in individuals with cancer. This represents a vital progression in transforming our scientific discoveries into a prospective new cancer treatment,” commented Kevin N. Heller, MD, Chief Medical Officer at Hummingbird Bioscience. “We acknowledge the importance of this occasion for patients and their relatives, and we anticipate collaborating closely with researchers throughout the study’s progression.”
Preliminary findings from the Phase I dose escalation are anticipated during the latter half of 2026.
Regarding HMBD-501
Various HER3-positive tumor environments have shown responsiveness to HER3-ADC treatment strategies. HMBD-501 was created by integrating Hummingbird Bioscience’s antibody discovery and engineering platform with advanced ADC technologies, aiming for a potentially improved efficacy and safety profile compared to earlier generation ADCs. Leveraging crucial proprietary technologies that yield a distinct molecule, HMBD-501 is positioned to emerge as a leading HER3-targeted ADC.
Concerning Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics firm operating at the intersection of artificial intelligence and human ingenuity to identify and advance groundbreaking medications for challenging diseases. The company’s computational and systems biology platforms have produced a robust pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates for oncology and autoimmune conditions. At Hummingbird Bioscience, a dedication to stringent scientific principles, collaborative effort, and intellectual honesty drives our commitment to expedite the progression of novel drugs from initial concept to clinical application. For further details, please visit , and connect with Hummingbird Bioscience on , , and .
Hummingbird Bioscience Media Relations:
Crystal Ho
+65 6979 5580
Hummingbird Bioscience Investor Relations:
